Search results
Found 99 matches for
Cost too high, benefit too small. No new drugs on the NHS
23 June 2025
The NHS will not be offering patients two new drugs that slow progression of Alzheimer’s Disease following a decision by the regulator, NICE. They have assessed that donanemab and lecanemab provide only a small benefit which does not justify the high cost to the health service.
DPUK approach attracts interest from beyond dementia sector
1 October 2018
Thanks to leaps forward in computing power, DPUK is able to harness highly advanced technical solutions to maintain data security and non-identifiability of millions of existing health records in the Data Portal. It’s a model that is globally unique for dementia research and one that’s increasingly attracting attention from other sectors.
DPUK makes its first ECR grant
2 July 2018
Dr Luke Whiley, an Early Career Researcher based at Imperial College London is awarded £1,500 to fund his attendance at a specialist training course in Utrecht.
Meet DPUK at the ARUK conference
20 March 2018
DPUK is delighted to have a big presence at the Alzheimer’s Research UK conference in London this year. See DPUK scientists present a broad range of new developments and findings in the poster exhibition and come and visit us at our stand. If you can't be there, stay tuned on Twitter – we'll be sharing our updates and insights throughout the programme.